HC Wainwright Has Weak Outlook for Precigen FY2026 Earnings

Precigen, Inc. (NASDAQ:PGEN) – Equities researchers at HC Wainwright reduced their FY2026 earnings per share estimates for shares of Precigen in a note issued to investors on Thursday, January 23rd. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will earn ($0.01) per share for the year, down from their prior forecast of $0.01. HC Wainwright currently has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Precigen’s current full-year earnings is ($0.33) per share. HC Wainwright also issued estimates for Precigen’s FY2027 earnings at $0.20 EPS and FY2029 earnings at $0.62 EPS.

Separately, JMP Securities reissued a “market outperform” rating and issued a $5.00 price objective on shares of Precigen in a research report on Tuesday, January 14th. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $7.00.

Precigen Trading Up 3.7 %

Shares of PGEN opened at $1.39 on Friday. The firm has a market capitalization of $407.09 million, a P/E ratio of -2.53 and a beta of 1.65. The stock’s fifty day simple moving average is $0.94 and its 200 day simple moving average is $1.06. Precigen has a twelve month low of $0.65 and a twelve month high of $1.93.

Institutional Investors Weigh In On Precigen

A number of hedge funds have recently made changes to their positions in the business. LexAurum Advisors LLC raised its holdings in shares of Precigen by 151.9% during the fourth quarter. LexAurum Advisors LLC now owns 691,544 shares of the biotechnology company’s stock valued at $775,000 after buying an additional 417,055 shares during the last quarter. SG Americas Securities LLC raised its holdings in Precigen by 27.9% during the fourth quarter. SG Americas Securities LLC now owns 57,641 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 12,578 shares in the last quarter. Synovus Financial Corp grew its position in Precigen by 100.0% in the third quarter. Synovus Financial Corp now owns 98,130 shares of the biotechnology company’s stock worth $93,000 after buying an additional 49,065 shares during the last quarter. Barclays PLC grew its position in Precigen by 190.4% in the third quarter. Barclays PLC now owns 189,353 shares of the biotechnology company’s stock worth $179,000 after buying an additional 124,141 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in Precigen by 4.8% in the third quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock worth $3,075,000 after buying an additional 149,829 shares during the last quarter. Institutional investors own 33.51% of the company’s stock.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.